title: [Clinical evaluation of nuclear matrix protein 22 as urinary marker of transitional cell carcinoma of bladder].
abstract: OBJECTIVES. Biomarkers (BTA, NMP22, FDP etc.) have been and continue to be evaluated as adjuncts or substitutes for cystoscopy, which is invasive and uncomfortable for some patients. Nuclear matrix protein-22 (NMP22) is involved in the regulation of nuclear processes. The main objective of the present study is to evaluate the clinical utility of urinary NMP22 as a tumor marker in the follow-up of transitional cell carcinoma (TCC) of the bladder. MATERIALS AND METHODS. The study included 62 patients undergoing follow-up, who had had TCC of bladder but who were disease-free at the beginning of the study, as confirmed by cystoscopy. Urine samples were collected for urinary cytology and NMP22 test before the cystoscopy. All samples were processed according to the instructions provided with the manufacturer's kit instructions. Results. 12 cases of TCC recurrences were detected with biopsy. Cystoscopy was positive in 8 cases, NMP22 test was positive in 11 cases, and in only one case the cytopathology yielded positive results. In 14 cases NMP22 resulted as false positive. CONCLUSIONS. Urinary NMP22 appeared to be a potential tumor marker for detecting TCC of the bladder, which might rise the sensitivity of cystoscopy especially in high-grade cancer surveillance more than cytology might do.
authors.forename: R F
authors.initials: RF
authors.lastname: Liotta
authors.forename: F
authors.initials: F
authors.lastname: Mangiapia
authors.forename: M L
authors.initials: ML
authors.lastname: Tarantino
authors.forename: S
authors.initials: S
authors.lastname: Di Meo
authors.forename: V
authors.initials: V
authors.lastname: Mirone
authors.forename: C
authors.initials: C
authors.lastname: Pavone